Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on May 25, 2021 5:48pm
204 Views
Post# 33264774

HHS to Dedicate $4.8 Billion for HRSA COVID-19 Testing

HHS to Dedicate $4.8 Billion for HRSA COVID-19 Testing

HHS to Dedicate $4.8 Billion from American Rescue Plan to COVID-19 Testing for the Uninsured

Today, the US Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), is announcing that it is dedicating $4.8 billion from the American Rescue Plan (ARP) to support the HRSA COVID-19 Uninsured Program. This funding will allow the program to continue reimbursing health care providers for testing uninsured individuals for COVID-19. As of May 19, 2021, the program has issued nearly $4 billion in testing reimbursements to providers.

“As we vaccinate the country, let’s continue taking the preventive measures necessary to keep the virus under control and prevent it from spreading. Testing remains critical and now it’s available at no cost to those who need it,” said HHS Secretary Xavier Becerra. “This funding will help ensure everyone has access to testing regardless of whether they have health insurance.”

There are approximately 29 million uninsured individuals living in the United States. https://www.hhs.gov/about/news/2021/05/25/hhs-to-dedicate-billions-from-the-american-rescue-plan-for-the-uninsured.html

Collection already started selling HRSA funded covid testing, infact all the covid-19 tests available on https://testbeforeyougo.com/ are built in combo. They are not selling single test anymore unless clients wants to pay with credit card. This way per client revenue is much higher compare to a few weeks ago. Here is an example https://a.flexbooker.com/widget/67a9bda2-bd71-43cb-aead-9015cb033887?locationId=21655#chooseService
 
Collection sites are in an advantageous position as they already started offering HRSA funded covid-19 testing. Now with this added $4.8 Billion funds to HRSA for covid-19 testing for uninsured people offer a great opportunity for collection sites. 
<< Previous
Bullboard Posts
Next >>